The company developed CF102 for the treatment of liver cancer and other liver diseases.
Can-Fite BioPharma Ltd. (TASE:CFBI) is moving forward with the development of its CF102 drug for the treatment of liver diseases, including liver cancer. The company said it had successfully completed the first stage of its Phase I clinical trials on humans.
The trials, which are being carried out in the US by the Contract Research Organization, commenced after Can-Fite recently obtained approval from the US Food and Drug Administration (FDA). The drug has been tested on healthy subjects, with dosages increased in several stages. The initial dosage produced satisfactory results in subjects, and Can-Fite will now increase the dosage in the next stage of the trial.
CF102, which was developed on the basis of Can-Fite's technology platform, is a targeted drug that binds with high affinity to the A3 adenosine receptor. This receptor is highly expressed on the surface of cancer cells but not on normal cells. CF102 binds to its target on cancer cells and triggers programmed cell death (apoptosis).
Published by Globes [online], Israel business news - www.globes.co.il - on February 17, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008